Brief: Citius Pharmaceuticals Completes Enrollment In Pivotal Phase 3 Trial Of Its Mino-Lok® Therapeutic To Salvage Catheters
02/01/2024 13:33
Jan 2 (Reuters) - Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS COMPLETES ENROLLMENT IN PIVOTAL
PHASE 3
TRIAL OF ITS MINO-LOK® THERAPEUTIC TO SALVAGE CATHETERS
* TOPLINE RESULTS EXPECTED 2Q 2024
Source text for Eikon: ID:nPn1HHqMMa
Further company coverage: CTXR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules